feed,title,long_url,short_url
Benzinga,Astellas Pharma - Seagen's Enfortumab Shows 36% Pathologic Complete Response In Bladder Cancer Patients,https://benzinga.com/general/biotech/22/02/25629094/astellas-pharma-seagens-enfortumab-shows-36-pathologic-complete-response-in-bladder-cancer-patien,https://bit.ly/365gUZK
